Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

A375 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (5) Aquaporin (1) Calcium Channel (1) CDK (1) DGK (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (5) Drug Derivative (1) Early 2 Factor (E2F) (1) Endogenous Metabolite (3) ERK (7) FAK (1) Ferroptosis (1) FGFR (1) Fungal (2) Haspin Kinase (1) HBV (2) HDAC (1) Histone Methyltransferase (1) HSP (1) IAP (1) JAK (2) MEK (5) Melanocortin Receptor (1) Microtubule/Tubulin (1) Organoid (1) p38 MAPK (1) Parasite (1) PD-1/PD-L1 (1) PROTACs (4) Raf (4) Ras (1) Sirtuin (2) Src (1) STAT (4) TMV (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (1) Tyrosinase (1) VEGFR (3)
By Research Areas:	Cancer (56) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

By Targets:

ADC Cytotoxin (1)

Akt (1)

Aldehyde Dehydrogenase (ALDH) (1)

Apoptosis (5)

Aquaporin (1)

Calcium Channel (1)

CDK (1)

DGK (1)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (5)

Drug Derivative (1)

Early 2 Factor (E2F) (1)

Endogenous Metabolite (3)

ERK (7)

FAK (1)

Ferroptosis (1)

FGFR (1)

Fungal (2)

Haspin Kinase (1)

HBV (2)

HDAC (1)

Histone Methyltransferase (1)

HSP (1)

IAP (1)

JAK (2)

MEK (5)

Melanocortin Receptor (1)

Microtubule/Tubulin (1)

Organoid (1)

p38 MAPK (1)

Parasite (1)

PD-1/PD-L1 (1)

PROTACs (4)

Raf (4)

Ras (1)

Sirtuin (2)

Src (1)

STAT (4)

TMV (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

Topoisomerase (1)

Tyrosinase (1)

VEGFR (3)

By Research Areas:

Cancer (56)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N10335

Harringtonolide 1 Publications Verification	FAK	Inflammation/Immunology Cancer
Harringtonolide is a potent RACK1 inhibitor (IC₅₀=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .

HY-153469

Benzyl DC-81	ADC Cytotoxin	Cancer
Benzyl DC-81 (Compound 6a) is an anticancer agent with antiproliferative activity against A375 and MCF-7 cells .

HY-16667

HLM006474 5+ Cited Publications	Early 2 Factor (E2F)	Cancer
HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC₅₀ of 29.8 µM in A375 cells.

HY-120607

Chevalone C	Parasite	Infection Cancer
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC₅₀ value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .

HY-153864

PROTAC MEK1 Degrader-1	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a MEK1 inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells .

HY-162900

HSP90-IN-32	HSP	Cancer
HSP90-IN-32 is a Hsp90 C-terminal inhibitor that displays anti-proliferative activities against SKMel173, SKMel103, SKMel19 and A375 cells with IC₅₀ values of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM , respectively. HSP90-IN-32 is promising for research of anti-cancer agents .

HY-144271

RAF-IN-1	Raf	Cancer
RAF-IN-1 is a potent b/cRAF inhibitor with an IC₅₀s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAF ^wt, and bRAF ^V600E. RAF-IN-1 shows cell growth inhibition with GI₅₀s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAF ^V600E mutation, respectively .

HY-153445A

MEK-IN-6 hydrate	MEK	Cancer
MEK-IN-6 hydrate (compound 69) is a MEK inhibitor. MEK-IN-6 hydrate has an IC₅₀ of 2 nM for A375 cells .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-161882

PROTAC SMARCA2 degrader-8	PROTACs	Cancer
PROTAC SMARCA2 degrader-8 (compound 1) is a potent SMARCA2 degrader with a DC₅₀ of 28nM in A375 cells .

HY-122506

Salviolone	STAT	Cancer
Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .

HY-N3838

Epitulipinolide diepoxide	Others	Cancer
Epitulipinolide diepoxide (compound 9) is a natural compound isolated from the herbs of Liriodendron chinense (Hemsl.) Sarg. Epitulipinolide diepoxide displays cytoxicity in A375 cells, with the IC₅₀ of 52.03 μM .

HY-171186

EAPB0202	Drug Derivative	Cancer
EAPB0202 is an imidazolium and quinoxaline derivative. EAPB0202 shows significant cytotoxicity to A375 human melanoma cell line with an IC₅₀ of 2.35 μM. EAPB0202 can be used in the study of cancer .

HY-128224

Antiproliferative agent-13	Others	Cancer
Antiproliferative agent-13 (compound 16c) shows an antiproliferative activity against human A375 cells with an IC₅₀ value of 32.7 nM. Antiproliferative agent-13 can be used for the research of cancer .

HY-169298

Ferroptosis-IN-15	Ferroptosis	Cancer
Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC₅₀s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .

HY-13323

CX-5461 40+ Cited Publications	DNA/RNA Synthesis	Cancer
CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC₅₀s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-12842

UC-112	IAP Apoptosis	Cancer
UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).

HY-153445

MEK-IN-6	ERK MEK	Cancer
MEK-IN-6 (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). MEK-IN-6 can be used for research of cancer .

HY-13323A

CX-5461 dihydrochloride 40+ Cited Publications	DNA/RNA Synthesis	Cancer
CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC₅₀s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC₅₀ ≥25 μM).

HY-147734

Calpain Inhibitor-2	Calcium Channel	Cancer
Calpain Inhibitor-2 (compound 5) is a peptide inhibitor of μ-calpain (Ki=9 nM). Calpain Inhibitor-2 exhibits antiproliferative activity against melanoma cell lines (A-375 and B-16F1) and PC-3 prostate cancer cells in vitro .

HY-N0201

Atractylenolide I 3 Publications Verification	TNF Receptor Toll-like Receptor (TLR) JAK STAT	Cancer
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-147788

hDHODH-IN-9	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC₅₀ of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases .

HY-N7484

(−)-Voacangarine	Fungal	Cancer
(−)-Voacangarine is an indole alkaloid, which exhibits cytotoxic effects against cancer cells HepG2, A375, MDA-MB-231, SH-SY5Y, and CT26 with IC₅₀ of 5~20 mg/mL. (−)-Voacangarine inhibits the cultivation of Saccharomyces cerevisiae wildtype and repair-deficient mutants .

HY-117872

Sartorypyrone A 20-O-Acetylsartorypyrone D	Fungal	Infection
Sartorypyrone A (20-O-Acetylsartorypyrone D) is a monocyclic terpenoid isolated from the soil fungus Neosartorya fischeri. Sartorypyrone A exhibits in vitro growth inhibitory activity against MCF-7, NCI-H460, and A375-C5 cell lines, and has potential anticancer properties.

HY-15816A

Ulixertinib hydrochloride 30+ Cited Publications BVD-523 hydrochloride; VRT752271 hydrochloride	ERK	Cancer
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

HY-13323R

CX-5461 (Standard)	DNA/RNA Synthesis	Cancer
CX-5461 (Standard) is the analytical standard of CX-5461. This product is intended for research and analytical applications. CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-15816

Ulixertinib 30+ Cited Publications BVD-523; VRT752271	ERK	Cancer
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

HY-N12834

Ecdysoside B	Others	Inflammation/Immunology Cancer
Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .

HY-N0201R

Atractylenolide I (Standard)	TNF Receptor Toll-like Receptor (TLR) JAK STAT	Cancer
Atractylenolide I (Standard) is the analytical standard of Atractylenolide I. This product is intended for research and analytical applications. Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-158027

B-Raf IN 17	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-N13739

Taraxinic acid	Tyrosinase	Cancer
Taraxinic acid can be found in the roots of Taraxacum flavostylum and Taraxacum lucidum. It is a Tyrosinase inhibitor that dose-dependently inhibits Tyrosinase activity, showing approximately 54.5% inhibition at a concentration of 50 μg/mL. Taraxinic acid has an IC₅₀ of 83.2 μM against melanoma cells A375 and HTB140, and an IC₅₀ of 60.4 μM against melanoma cells WM793, with activity being both dose- and time-dependent. Taraxinic acid holds promise for research in the field of anticancer therapy .

HY-169086

KL-465	PROTACs	Cancer
KL-465 is a PROTAC degrader for MAGE-A3, that degrades MAGE-A3 with a DC₅₀ of 2 μM in HeLa cell. KL-465 inhibits viability of MAGE-A3 positive cancer cell HCT116, A375 and HeLa. (Blue: Ligand for E3 ligase (HY-151227); Black: Linker (HY-W679862); Pink: Ligand for target protein (HY-169087))

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Cancer
MSG606 TFA is a potent human MC1 receptor antagonist (IC₅₀=17 nM). MSG606 TFA also partial agonist at human MC3 and MC5 receptors (EC₅₀ values are 59 and 1300 nM, respectively). MSG606 TFA exhibits binding affinity for A375 melanoma cells in vitro. MSG606 TFA reverses the induced hyperalgesia in female mice, with no effect in male mice.

HY-164474

DS03090629	MEK	Cancer
DS03090629 is an orally active MEK inhibitor that inhibits MEK activity in an ATP-competitive manner. DS03090629 exhibits high affinity for both MEK and phosphorylated MEK, with K_d values of 0.11 and 0.15 nM, respectively. It effectively inhibits the proliferation of BRAF-mutant overexpressing melanoma cell lines, with IC₅₀ values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 holds potential value in the field of anti-melanoma therapy .

HY-153341

CFT1946	PROTACs Raf	Cancer
CFT1946 is an orally active, CRBN-based and mutant-selective bifunctional degradation activating compound (BiDAC ^™) degrader of BRAF ^V600E with a DC₅₀ of 14 nM in A375 cells. CFT1946 is capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations, and the p61-BRAF ^V600E splice variant. CFT1946 can be used in tumor research .

HY-169409

VEGFR-2-IN-59	VEGFR	Cancer
VEGFR-2-IN-59 (Compound 3h) is an inhibitor for VEGFR2 with an IC₅₀ of 3.73 µM. VEGFR-2-IN-59 exhibits cytotoxicity in cancer cell A549, HT-29, A375, MCF7 and NHDF with IC₅₀ of 20.91, 19.70, 9.63, 17.43 and 20.71 μM. VEGFR-2-IN-59 inhibits formation of tubular structure and exhibits anti-angiogenic property .

HY-161628

Tapcin	Topoisomerase	Cancer
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC₅₀ of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC₅₀s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model .

HY-153738

ERK1/2 inhibitor 9	ERK	Cancer
ERK1/2 inhibitor 9 (Probe 1) is a covalent ERK1/2 inhibitor. ERK1/2 inhibitor 9 shows sub-micromolar activity in cells (A375 GI50=0.47 μM). ERK1/2 inhibitor 9 causes the downregulation of phospho-ERK1/2. ERK1/2 inhibitor 9 tagged trans-cyclo-octene (TCO) and Tz-Thalidomide (tetrazine tagged Thalidomide) can form the corresponding ERK-CLIPTAC to elicit degradation of ERK1/2 .

HY-138098

Sartorypyrone B	Endogenous Metabolite	Cancer
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-121255

(-)-Cryptopleurine (R)-Cryptopleurine; NSC 19912	TMV	Cancer
(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC₅₀=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC₅₀=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.

HY-117991

DW10075	VEGFR	Cancer
DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC₅₀s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.

HY-164781

KOTX1	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .

HY-149005

PRMT5-IN-19	Histone Methyltransferase	Cancer
PRMT5-IN-19 (Compound 41) is an selective orally active non-nucleoside PRMT5 inhibitor with IC₅₀ values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). PRMT5-IN-19 can occupy the SAM-binding pocket in PRMT5 and block methyltransferase activity, which displays good selectivity over other PRMTs and PKMTs. PRMT5-IN-19 inhibits cell proliferation by inducing cell apoptosis, and can be used for cancer-related research .

HY-163356

Tubulin polymerization-IN-60	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-60 (BF3) is a tubulin polymerization inhibitor with anticancer activity. Tubulin polymerization-IN-60 (BF3) belongs to the colchicine binding site inhibitors (CBSIs) and disturbs cell cycle progression leading to G2/M arrest and apoptosis .

HY-163595

Pan-RAS-IN-4	Ras	Cancer
Pan-RAS-IN-4 (compound 2) is a potent inhibitor of RAS, with the IC₅₀ of ＜ 100 nM for KRAS G12D. Pan-RAS-IN-4 plays an important rile in cancer research .

HY-126214S

JH-RE-06-d6	DNA/RNA Synthesis	Cancer
JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_i=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .

HY-163858

Haspin-IN-4	Haspin Kinase	Cancer
Haspin-IN-4 (Compound 60) is a selective inhibitor of Haspin with an IC₅₀ value of 0.01 nM. Haspin-IN-4 possesses anticancer activity and can be used in cancer research .

HY-164039

Talorasib	Others	Cancer
Talorasib (compound 1-2) has antitumor activity .

HY-B0150A

Nicotinamide Hydrochloride Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride	Sirtuin Endogenous Metabolite HBV	Infection Cancer
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .

HY-B0150

Nicotinamide Maximum Cited Publications 55 Publications Verification Niacinamide; Nicotinic acid amide	Organoid Endogenous Metabolite Sirtuin HBV	Cancer
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

Cat. No.	Product Name	Target	Research Area